Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 257

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 257
---
 orientation when selecting members of our board of directors.

Any stockholder who wishes
to recommend a candidate for consideration by the committee as a nominee for director should follow the procedures described in our proxy
statement to be filed with the SEC in connection with our 2024 special meeting of stockholders within 120 days after the end of the fiscal
year ended December 31, 2023. The nominating and corporate governance committee will also consider whether to nominate any person proposed
by a stockholder in accordance with the provisions of our Bylaws relating to stockholder nominations.

<div align='center'>149</div>

Compensation Committee Interlocks and Insider Participation

During the fiscal year ended
December 31, 2023, Mr. Ehrlich served as the Chief Executive Officer of our predecessor, PBAX. In connection with the Business Combination,
on February 14, 2024, Mr. Ehrlich ceased to be an officer of PBAX. Mr. Ehrlich served as a member of our Compensation Committee from
the closing of the Business Combination until his appointment as our interim Chairman and Chief Executive Officer. Other than Mr. Ehrlich,
during the fiscal year ended December 31, 2023, none of the members of our Compensation Committee has ever been one of our officers or
employees. None of our executive officers currently serves, or has served, as a member of our board of directors or Compensation Committee
of any entity that has one or more executive officers serving as a member of our board of directors or Compensation Committee.

Board Diversity

Board diversity and inclusion
is critical to our success. While we do not have a formal policy on board of directors diversity, the board of directors is committed
to building a board of directors that consists of the optimal mix of skills, expertise, and diversity capable of effectively overseeing
the execution of our business and meeting our evolving needs, with diversity reflecting gender, age, race, ethnicity, background, professional
experience and perspectives. Our nominating and corporate governance committee considers the value of diversity on the board of directors
in evaluating director nominees. Accordingly, the nominating and corporate governance committee’s evaluation of director nominees
includes consideration of their ability to contribute to the diversity of personal and professional experiences, opinions, perspectives
and backgrounds on the board of directors.

The matrix below provides
certain highlights of the composition of our board of directors based on self-identification. Each term used above and in the matrix
below has the meaning given to it in Nasdaq Listing